IBRX280121C00001000
IBRX Jan 21 2028 1.00 Call
optionOPRA
InactiveOct 6, 2026
9.25USD-2.632%(-0.25)1Vol75OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
1
Expiration
Jan 21, 2028
DTE
458d
Moneyness
ITM
Intrinsic
$7.48
IBRX 1 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 20, 2026 | 31d | $8.65 | -5.98% | 1 | 43 |
| Jan 15, 2027 | 87d | $9.44 | +11.06% | 10 | 222 |
| Mar 19, 2027 | 150d | $6.12 | +0.00% | 20 | 0 |
| Apr 16, 2027 | 178d | — | — | 0 | 0 |
| May 21, 2027 | 213d | $8.26 | +0.00% | 10 | 10 |
| Aug 20, 2027 | 304d | — | — | 0 | 0 |
| Nov 19, 2027 | 395d | — | — | 0 | 0 |
| Jan 21, 2028 | 458d | $9.25 | -2.63% | 1 | 75 |
| Mar 17, 2028 | 514d | $7.61 | +17.08% | 5 | 15 |
| Jan 19, 2029 | 822d | $8.17 | -12.62% | 6 | 52 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.